ATR-002

DRUG2 trials

Sponsors

Atriva Therapeutics GmbH

Conditions

COVID-19Healthy

Phase 1

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib

CompletedNCT05555823

Atriva Therapeutics GmbHHealthy

Start: 2022-06-23End: 2023-07-20Updated: 2023-08-01

Phase 2

Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19

TerminatedNCT04776044

Atriva Therapeutics GmbHCOVID-19

Start: 2021-04-12End: 2022-08-09Updated: 2022-09-22

Related Papers

Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial.

2023-10-0410 citations